References
- Saydam G, Haznedaroglu IC, Kaynar L, et al. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Expert Opin Pharmacother. 2016;17(14):1851–1858.
- Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–2259.
- Hochaus D, Saglo G, Hugher TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.Leukemia. 2016 May;30(5):1044–1054. Published online 2016 Mar 4. Pre-published online 2016 Feb 3. DOI:10.1038/leu.2016.5.